Endocannabinoids and Metabolic Disorders.
Handbook of experimental pharmacology, January 2015
Gatta-Cherifi, Blandine, Cota, Daniela, Blandine Gatta-Cherifi, Daniela Cota
Roger G. Pertwee
The endocannabinoid system (ECS) is known to exert regulatory control on essentially every aspect related to the search for, and the intake, metabolism and storage of calories, and consequently it represents a potential pharmacotherapeutic target for obesity, diabetes and eating disorders. While the clinical use of the first generation of cannabinoid type 1 (CB1) receptor blockers has been halted due to the psychiatric side effects that their use occasioned, recent research in animals and humans has provided new knowledge on the mechanisms of actions of the ECS in the regulation of eating behavior, energy balance, and metabolism. In this review, we discuss these recent advances and how they may allow targeting the ECS in a more specific and selective manner for the future development of therapies against obesity, metabolic syndrome, and eating disorders.
|Members of the public||2||100%|
|Readers by professional status||Count||As %|
|Student > Doctoral Student||5||13%|
|Student > Bachelor||4||10%|
|Student > Ph. D. Student||4||10%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||10||26%|
|Agricultural and Biological Sciences||4||10%|
|Pharmacology, Toxicology and Pharmaceutical Science||3||8%|
|Nursing and Health Professions||3||8%|
|Biochemistry, Genetics and Molecular Biology||2||5%|